The projected $183.2 billion wearable market by 2031 isn't just about consumer fitness trackers; it's a data pipeline revolution for biotech. Allied Market Research's 12.75% CAGR forecast, released April 21, 2026, highlights AI and IoT as growth drivers, but the underreported angle is how continuous physiological monitoring is reshaping clinical trials. Wearables like continuous glucose monitors (CGMs) and smart patches are generating high-frequency biomarker data, enabling more sensitive endpoints and reducing trial durations.
Biotech Applications: Beyond Monitoring
In therapeutic areas like diabetes, cardiology, and neurology, wearables are moving from adjunct tools to primary data sources. For example, Dexcom's G7 CGM is used in trials for GLP-1 agonists to track glycemic variability beyond HbA1c. In Alzheimer's disease, digital biomarkers from wearables—such as gait analysis and sleep patterns—are being validated in trials like the Alzheimer's Disease Neuroimaging Initiative (ADNI). This shift allows for earlier detection of treatment effects and more personalized dosing regimens.
Wearables are transforming from consumer gadgets to FDA-qualified clinical tools, with over 50 digital health technologies now cleared for use in trials.
Competitive Landscape and Investment Implications
The wearable surge is creating a new layer of competition among biotech, medtech, and tech firms. Companies like Verily (Alphabet's life sciences arm) are developing study watches for longitudinal health data, while startups like Empatica focus on neurological disorders. For investors, this means evaluating biotech pipelines not just on drug mechanisms but on their integration with wearable data streams. Firms that leverage these tools for decentralized trials may see lower costs and faster regulatory approvals, as seen in Pfizer's use of wearables for COVID-19 vaccine monitoring.
Looking ahead, the next 12 months will test whether wearable-derived endpoints gain regulatory acceptance beyond pilot studies. The FDA's Digital Health Center of Excellence is reviewing frameworks for digital biomarkers, with decisions expected in 2027. Biotechs investing in companion wearable strategies—such as those in metabolic disease or rare disorders—could capture early-mover advantages, but must navigate data privacy and validation hurdles. As the market grows, the winners will be those who treat wearables not as accessories but as integral components of therapeutic development.
